Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 2, 2012 Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Down By 6.40% ($0.24) From $3.750 After BUYINS.NET Report Predicted Weakness After Ea
November 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, October 31st 2012 stating that Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=idix&id=323648
At the time this story was written, Idenix Pharmaceuticals Inc (NASDAQ:IDIX) is Down By 6.40% ($0.24) From $3.750 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) - Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company primarily focuses its research and development on the treatment for hepatitis C virus. The company develops nucleoside/nucleotide polymerase inhibitors, including IDX184, a liver-targeted nucleotide prodrug candidate, which is in phase IIa clinical trial; and IDX102 that completed late-stage preclinical development. It also develops IDX375, a novel palm-binding polymerase inhibitor that is in phase I program; IDX320, a protease inhibitor candidate, which is in phase I healthy volunteer clinical study; and NS5A inhibitors. In addition, the company licensed its telbivudine (Tyzeka/Sebivo), a drug for the treatment of hepatitis B virus, to Novartis Pharma AG; and GSK2248761, a drug candidate from the class of compounds known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of human immunodeficiency virus type 1 and acquired immune deficiency syndrome to GlaxoSmithKline. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com